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Development of Therapeutic siRNAs
for Pachyonychia Congenita
Frances J.D. Smith1, Robyn P. Hickerson2, Jane M. Sayers1, Robert E. Reeves3, Christopher H. Contag3,4,
Devin Leake5, Roger L. Kaspar2 and W.H. Irwin McLean1
Pachyonychia congenita (PC) is an autosomal-dominant keratin disorder where the most painful, debilitating
aspect is plantar keratoderma. PC is caused by mutations in one of four keratin genes; however, most patients
carry K6a mutations. Knockout mouse studies suggest that ablation of one of the several K6 genes can be
tolerated owing to compensatory expression of the others. Here, we have developed potent RNA interference
against K6a as a paradigm for treating a localized dominant skin disorder. Four small interfering RNAs (siRNAs)
were designed against unique sequences in the K6a 30-untranslated region. We demonstrated near-complete
ablation of endogenous K6a protein expression in two keratinocyte cell lines, HaCaT and NEB-1, by transient
transfection of each of the four K6a siRNAs. The siRNAs were effective at very low, picomolar concentrations.
One potent lead K6a inhibitor, which was highly specific for K6a, was tested in a mouse model where reporter
gene constructs were injected intradermally into mouse paw and luciferase activity was used as an in vivo
readout. Imaging in live mice using the Xenogen IVIS system demonstrated that the K6a-specific siRNA strongly
inhibited bicistronic K6a-luciferase gene expression in vivo. These data suggest that siRNAs can specifically and
very potently target mutated genes in the skin and support development of these inhibitors as potential
therapeutics.
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INTRODUCTION
Keratins belong to the family of intermediate filament
proteins and form cytoskeletal networks within all epithelial
cells (Omary et al., 2004). Keratins are expressed in a tissue-
and differentiation-specific manner and it is predicted that
there is some degree of functional redundancy in tissues
where multiple keratins are expressed (Coulombe and
Omary, 2002). Of the 54 epithelial keratin genes in the
human genome (Schweizer et al., 2006), 21 are currently
known to be linked to human diseases characterized by
fragility of specific subsets of epithelial tissues. Because
keratins form highly polymeric structures, the vast majority of
keratin mutations, mainly missense or small in-frame inser-
tion/deletion mutations, disrupt cytoskeletal function by
dominant-negative interference (Irvine and McLean, 1999).
Gene therapy aimed at these dominant diseases might
therefore specifically ablate the mutant allele; however, this
requires designing allele-specific silencing reagents for each
individual mutation (Kaspar, 2005; Lewin et al., 2005). Most
keratin disorders are genetically heterogeneous in terms of
having two or more paired keratin genes that phenocopy the
disorder, each of which has an associated spectrum of
pathogenic mutations (Lane and McLean, 2004). Therefore,
designing specific silencing reagents for each mutation is a
considerable task in terms of inhibitor design, safety testing,
and passing regulatory hurdles for human use. However, in
some epithelial tissues where functional redundancy of
keratin genes has been shown, it may be possible to inhibit
both wild-type and mutant alleles to therapeutic effect. The
palmoplantar epidermis is one such tissue where at least 10
epithelial keratins are expressed (Swensson et al., 1998);
therefore, this tissue, representing a relatively small area of
the epidermis and one in which keratin redundancy might be
exploited, is a favorable site for testing new therapies aimed
at cutaneous gene inhibition (Kaspar, 2005).
Pachyonychia congenita (PC) is a rare, autosomal-domi-
nant keratin disorder predominantly characterized by hyper-
trophic nail dystrophy, palmoplantar keratoderma, oral
leukokeratosis, and other ectodermal defects (Leachman
et al., 2005; Smith et al., 2005). Currently, there is no
effective treatment for the disease. PC can be subdivided into
See commentary on pg 7ORIGINAL ARTICLE
50 Journal of Investigative Dermatology (2008), Volume 128 & 2007 The Society for Investigative Dermatology
Received 29 May 2007; accepted 21 June 2007; published online 30 August
2007
1Epithelial Genetics Group, Human Genetics Unit, Ninewells Hospital and
Medical School, University of Dundee, Dundee, UK; 2TransDerm Inc.,
Santa Cruz, California, USA; 3Molecular Imaging Program at Stanford (MIPS),
Stanford University School of Medicine, Stanford, California, USA;
4Departments of Pediatrics, Radiology, and Microbiology & Immunology,
Stanford University School of Medicine, Stanford, California, USA and
5Thermo Fisher Scientific (Dharmacon Inc.), Lafayette, Colorado, USA
Correspondence: Dr Frances J.D. Smith, Human Genetics Unit, Ninewells
Hospital and Medical School, Dundee, DD1 9SY, UK.
E-mail: f.j.d.smith@dundee.ac.uk
Abbreviations: CNV, copy number variation; EGFP, enhanced green
fluorescent protein; EYFP, enhanced yellow fluorescent protein; RNAi, RNA
interference; siRNA, small interfering RNA; PC, pachyonychia congenita;
UTR, untranslated region
two major variants: PC-1 (OMIM no. 167200) and PC-2
(OMIM no. 167210) as reviewed recently (Leachman et al.,
2005; Smith et al., 2005). At the molecular level, hetero-
zygous mutations in keratin K6a or K16 cause PC-1 whereas
those in K6b or K17 cause PC-2 (Bowden et al., 1995;
McLean et al., 1995; Smith et al., 1998). Of the epithelial
tissues that are disrupted by these mutant keratins in PC
patients, the main therapeutic target is the plantar epidermis,
because focal keratoderma is the most painful and debilitat-
ing aspect of the disorder (Leachman et al., 2005). It has also
been shown that individuals carrying mutations in K16, and
presumably other PC-related keratins, can present clinically
with focal plantar keratoderma alone, without other obvious
ectodermal phenotypes (Shamsher et al., 1995; Smith et al.,
2000, 2005). This further expands the patient population who
might benefit from therapies aimed at PC, and furthermore,
lessons learned from PC may well be adapted for other
keratin genes.
Knockout mouse studies of the two major K6 genes, K6a
and K6b, have shown that these genes exhibit functional
redundancy – knocking out one of these keratins has little or
no phenotypic consequences and only when both are ablated
does an overt phenotype occur in the oral epithelia (Wojcik
et al., 2000, 2001; Wong et al., 2000; Wong and Coulombe,
2003). Importantly, these studies showed that knockout of
either K6a or K6b produces no obvious effect on the
palmoplantar epidermis in mice. Of particular importance
to this study, a number of recent reports have shown that the
human genome exhibits far more structural variation between
individuals in the population than was previously recognized,
as reviewed recently (Kehrer-Sawatzki, 2007). Specifically,
more than 3,500 regions of the genome have so far been
proven by multiple molecular methods to exhibit copy
number variation (CNV), whereby relatively large stretches
of DNA, often involving entire genes or even clusters of
genes, are either duplicated or deleted in individuals within
the normal human population (Iafrate et al., 2004; Hinds
et al., 2006; McCarroll et al., 2006; Redon et al., 2006; Wong
et al., 2007). The most recent and comprehensive analysis of
CNV has shown that the type II keratin locus on 12q is
involved in a number of CNVs (Wong et al., 2007). Of
particular interest, in relation to PC, it was shown that 3 out of
95 normal individuals analyzed carried a heterozygous CNV
involving deletion of both the K6a and K6b genes and a
number of nearby type II hair keratin genes (Wong et al.,
2007). CNV has been shown to behave in a normal
Mendelian manner and therefore from the Hardy–Weinberg
calculations, about 1 in 4,000 individuals in the human
population will be homozygous for this deletion and there-
fore be null for K6a and nearby genes (http://www.chang
bioscience.com/genetics/hardy.html). Because this would
equate to about 75,000 individuals in the United States
alone, we hypothesize that ablation of K6a in humans does
not produce a PC-like phenotype or else this very large
number of individuals would have come to clinical attention.
From the published studies on CNV in the human genome,
there is no evidence to suggest that these variants are not
inherited in a normal Mendelian manner nor is there any
evidence for lack of the Hardy–Weinberg equilibrium in the
population (Kehrer-Sawatzki, 2007). Thus, in view of the
evidence from transgenic mice and the emerging CNV data in
humans, we hypothesize that specific inhibition of K6a
expression, without altering the expression of K6b or the other
palmoplantar keratins, may have the potential to treat the
majority of PC patients, regardless of their individual mutations.
RNA interference (RNAi) is a naturally occurring gene-
silencing mechanism originally identified in Caenorhabditis
elegans and subsequently in mammalian cells, where it is
now routinely used as a research tool (Rana, 2007). This
process of sequence-specific, post-transcriptional inhibition
of gene expression has great potential to be developed as a
novel therapeutic approach for a number of disorders where
gene inhibition is predicted to be therapeutic (Bumcrot et al.,
2006). Skin disorders represent a good model for RNAi
therapy development because localized cutaneous applica-
tion of small interfering siRNA (siRNA) may be easier to
achieve than systemic administration or use of integrating
viral vector systems, both for proof-of-concept experiments in
cell culture or animal models and ultimately, treatment of
human subjects (Lewin et al., 2005).
Here, we present studies aimed at developing RNAi for
localized treatment of plantar keratoderma in PC and, by
targeting the 30-untranslated region (30-UTR) sequences often
ignored by siRNA design algorithms, we demonstrate
surprisingly potent efficacy of these gene inhibitors in both
keratinocyte cultures and a mouse model.
RESULTS
Inhibition of K6a expression
DNA sequence alignments of the cDNAs encoding human
K6a (Genbank RefSeq accession no. NM_005554) and K6b
(Genbank RefSeq accession no. NM_005555) revealed that
only a few isolated bases can distinguish these two genes in
terms of their protein-encoding sequences (data not shown).
However, these two genes differ significantly in their non-
coding 30-UTR sequences, allowing the design of four
inhibitors (designated K6a-S1, -S2, -S3, and -S4; see Table 1),
which were predicted to inhibit K6a expression without
affecting the expression of K6b or other type II keratin genes
due to significant sequence differences (Figure 1a). The four
Table 1. siRNA sequences
siRNA Sequence
K6a siRNA 1 50-GCACAAGUGACUAGUCCUAUU-30
K6a siRNA 2 50-CUAGUCCUAUGAUGUACAAUU-30
K6a siRNA 3 50-UCUUCUCUCUCUCUCUAUAUU-30
K6a siRNA 4 50-UCUGAGGCUGAGCAUUAUAUU-30
Lamin A/C 50-CUGGACUUCCAGAAGAACAUU-30
Non-specific control (NSC4) 50-UAGCGACUAAACACAUCAAUU-30
EGF-specific inhibitor 50-GCACCAUCUUCUUCAAGGAUU-30
1EGF, endothelial growth factor.
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K6a inhibitors were initially tested in human 293FT
embryonic kidney cells for inhibition of enhanced green
fluorescent protein (EGFP)-tagged K6a. Either K6a-specific,
EGFP-specific, or non-specific control siRNAs were co-
transfected into 293FT cells along with a K6a-enhanced
yellow fluorescent protein (EYFP) expression plasmid. IC50 is
a unit of measurement for the efficacy of inhibitors, such as
siRNA, and in this case is defined as the inhibitor concentra-
tion resulting in a 50% reduction in gene expression. All four
K6a-specific siRNAs strongly inhibited K6a expression, giving
highly favorable IC50 values between 0.03 and 0.1 nM as
determined by fluorescence-activated cell sorting analysis of
cells expressing the EYFP-tagged K6a protein (Figure 1b). As a
positive control, EGFP-specific siRNA inhibitor co-transfected
with the K6a-EYFP plasmid gave an IC50 of B0.1 nM (Figure
1b). The sequence target of this EGFP control inhibitor is
conserved in EYFP and other modified fluorescent proteins
derived from EGFP and it is known to be a potent siRNA in
cultured cells and in vivo using a mouse model system (Wang
et al., 2007). Thus, our K6a siRNAs were comparable in
potency to a recognized potent inhibitor, especially at the
low, picomolar concentrations that would be useful for
therapeutic application (Figure 1b). In contrast, no effect was
observed with the irrelevant control (NSC4) siRNA inhibitor
K6a-S1
1
0.8
N
or
m
al
iz
ed
 K
6a
-E
YF
P 
ex
pr
es
sio
n
0.6
0.4
0.2
EGFP siRNA
K6a-S1
K6a-S2
K6a-S3
K6a-S4
NSC4
0
siRNA concentration (nM)
K6a-S1
Specific K6a siRNA concentration (nM)
K6a-S2
K6a-S3
K6a-S4
K6a
K6b
0
0.
01
6
0.
06
3
0.
25 1 4
K6a
K6b
K6a
K6b
K6a-S2
K6a-S3
K6a-S4
N
o 
in
hi
bi
to
r
4 
nM
 
N
SC
4
0.
01
6
0.
06
3
0.
25
1 4
K6a
K6b
Figure 1. Sequence specificity and efficacy of K6a 30-UTR siRNAs. (a) Alignments of portions of the human K6a and K6b 30-UTR cDNA sequences, showing that
the target sequences of the four siRNAs (bold type) are located where several insertion/deletion and single-base substitutions occur between K6a and K6b.
(b) Normalized K6a-EYFP expression measured by FACS of 293FT cells transiently transfected with K6a-EYFP and the lead K6a siRNAs (K6a-S1, -S2, -S3, and -S4).
A potent EGFP siRNA (which also targets EYFP equally well) was used as a positive control. A non-specific control siRNA (NSC4) did not significantly affect
expression, even at high concentrations, whereas all four K6a inhibitors worked as well or better than the EGFP control inhibitor at low sub-nanomolar
concentrations. Bars on the graph represent the mean7SE. (c) Visual confirmation of K6a siRNA efficacy by wide-field imaging of 293FT cells transiently
transfected with K6a-EYFP and siRNAs over a range of inhibitor concentrations.
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(Figure 1b). Cells were also visualized by fluorescence
microscopy (Olympus CK40) 48 hours after transfection using
an EGFP filter set (Figure 1c), confirming by a different, more
visual method that these inhibitors are effective at picomolar
concentrations. No changes in cell density or morphology
were observed by bright field imaging (data not shown).
Inhibition of endogenous K6a in HaCaT and NEB-1 cells
Currently, there are no antibodies available to distinguish
between human K6a and K6b proteins and it is unlikely that
such reagents will emerge because there are only a few
isolated amino acids that differ between these proteins.
However, reverse transcriptase-PCR analysis using primers
specific to either K6a or K6b demonstrated that both
immortalized keratinocyte cell lines HaCaT and NEB-1 cells
express significant amounts of K6a and negligible amounts of
K6b (data not shown). This is in comparison with primary
keratinocyte cultures, which we have found to express high
levels of both K6a and K6b by reverse transcriptase-PCR (data
not shown). HaCaT and NEB-1 are therefore suitable cell
lines to test the efficacy of K6a siRNAs because inhibition of
K6a will not be masked by the expression of K6b. Initially, the
four K6a siRNAs were independently transfected at a final
concentration of 5 nM into HaCaT cells. Total protein extracts
were prepared at 24, 48, 72, 96, and 120 hours post-
transfection. Immunoblotting with an anti-K6 antibody
showed approximately 50% reduction of K6 protein expres-
sion with each of the four K6a siRNAs by 48 hours, which
increased to almost 100% loss of expression by 72–96 hours
(data not shown). From a separate ongoing study in the
laboratory, the half-life of epidermal keratins is of the order of
12–24 hours, consistent with the clearance time observed
here (McLean, unpublished data). Transfections were re-
peated and cytoskeletal extracts were prepared 96 hours after
transfection for protein staining of SDS–PAGE gels and
immunoblot analysis with a range of antibodies (Figure 2).
A highly significant decrease in the levels of K6 was
visualized in protein gels stained with Coomassie blue; all
other cytoskeletal proteins were unaffected (Figure 2a). This
was confirmed by staining blots with antibodies against K6,
K5, K8, K14, K16, K17, K18, K19, and lamin A/C. Although
there was almost 100% reduction of K6 with each of the four
K6a siRNAs, little or no change was observed in the levels of
all other keratins analyzed (Figure 2b). Interestingly, transfec-
tion with K6a-S3 did however lead to a slight reduction in the
amount of lamin A/C, indicative of possible off-target effects
(Figure 2b). The target sequence of K6a-S3 is not well
conserved in lamin A/C (which is also an intermediate
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Figure 2. Inhibition of endogenous K6a in HaCaT cells. (a) Coomassie blue staining of cytoskeletal extracts 96 hours after transfection with 5 nM K6a siRNAs
showing near-complete loss of K6a expression with all four K6a 30-UTR siRNAs; all other keratins were unaffected. (b) Immunoblotting of replicate gels as shown
in (a), with a range of anti-keratin antibodies, confirming the loss of K6a expression and normal expression of other keratins present in HaCaT cells.
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filament protein distantly related to keratins); therefore, this
result, which was consistent in replicate experiments in both
HaCaT and NEB-1 cells, does not have an obvious explana-
tion. The K6a-S3 sequence is, however, somewhat repetitive
and this may explain the non-specific effects. Thus, K6a-S3 is
not of sufficient specificity for further development toward
human use. All these efficacy and specificity experiments
were repeated on the NEB-1 cell line (Morley et al., 2003)
with identical results obtained (data not shown).
Specificity of K6a siRNAs
To confirm that the siRNAs did not affect the expression of
K6b, the most obvious candidate for off-target effects, a dual-
expression construct was made that expresses both FLAG-
tagged K6a and myc-tagged K6b to enable detection of each
K6 protein using antibodies against the specific epitope tags.
This construct was co-transfected into AD293 cells with each
of the four K6a siRNAs and total protein extracted 48 hours
after transfection. Analysis of extracts by Western blotting
showed essentially complete loss of K6a protein, whereas
levels of K6b were only slightly reduced (Figure 3).
K6a-S1 strongly inhibits reporter gene expression in vivo
Previously, we have shown that specific siRNAs (but not non-
specific controls) strongly inhibit epidermal EGFP/luciferase
transgene expression in vivo by intradermal injection into
mouse footpads (Wang et al., 2007). One of the potentially
therapeutic siRNAs developed here, K6a-S1, was chosen for
in vivo testing in mouse footpad by co-injection with a
bicistronic K6a-luciferase reporter construct. Using luciferase
activity as an in vivo readout, we were able to show that K6a-
S1, but not nonspecific controls, strongly inhibited K6a/
luciferase gene expression in mouse skin (Figure 4). Aver-
aging the bioluminescence readout from several mice, K6a/
luciferase reporter gene expression was found to be strongly
inhibited at the earliest time point examined (1 day) and
remained barely detectable over the 3-day course of the
experiment (Figure 4).
DISCUSSION
Treatment of autosomal-dominant skin disorders such as PC
requires the development of effective methods to reduce or
preferably, fully inactivate, the dominant-negative mutant
allele (Kaspar, 2005; Lewin et al., 2005). The recently
identified RNAi pathway and in particular, the availability
of siRNA specific to user-defined genetic sequence targets
offers a novel way to achieve this (Bumcrot et al., 2006;
Rana, 2007). In the case of PC, an unusual situation exists
where there is more than one copy of the affected gene (K6a
and K6b), with similar, overlapping expression patterns
(Smith et al., 1998) and where complete loss of K6a is
predicted from mouse knockouts to be tolerated owing to the
compensatory expression of K6b (Wojcik et al., 2000, 2001;
Wong et al., 2000; Wong and Coulombe, 2003). Further-
more, the recently identified CNV in the human genome
strongly suggests that homozygous ablation of the K6a/K6b
genes exists in as many as 1 in 4,000 humans, without
obvious pathology (Wong et al., 2007). This therefore opens
up the possibility for a gene-silencing approach that is
independent of the particular K6a mutation carried by an
individual patient. Careful genetic analysis of many affected
families has shown that K6a is the most common gene
mutated in PC (Smith et al., 2005). Therefore, this approach,
if successful, could treat the majority of patients with this
disease using a single gene-silencing reagent. This has the
considerable added advantage that only one reagent would
require toxicity testing, manufacture to current Good
Manufacturing Practice standards, and approval for human
use from the Food and Drug Administration or other
equivalent regulatory agencies outside the United States, all
of which represent considerable obstacles to therapy develop-
ment for orphan diseases affecting small numbers of
individuals (Epstein et al., 2006).
By targeting the 30-UTR of the K6a gene, we were able to
identify four highly efficacious siRNAs capable of essentially
ablating K6a expression in keratinocyte cell lines by
72–96 hours. The general guidelines for siRNA design suggest
that the 50- and 30-UTR sequences should be avoided as the
target site (Reynolds et al., 2004). The rationale is that some
genes may have alternate spliced exons that generate mRNA
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Figure 3. K6a 30-UTR siRNAs do not significantly affect K6b expression.
(a) Immunoblot of total protein extracts from AD293 cells transfected with
dual expression vector expressing FLAG epitope-tagged K6a and myc epitope-
tagged K6b in combination with test siRNAs. Blot stained with Ponceau S to
demonstrate equal protein loading in each lane. (b) Replica immunoblot
shown in (a), stained with anti-FLAG antibody to show K6a-FLAG expression.
All four K6a siRNAs completely knock out K6a expression, whereas cells
transfected with K6a/K6b plasmid alone or an irrelevant siRNA show high
levels of K6a-FLAG expression. (c) Replica immunoblot shown in (a), stained
with anti-myc antibody to show K6b-myc expression. Only a slight reduction
in K6b-myc expression is seen with the four K6a-specific siRNAs.
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species with alternate 50- and/or 30-UTRs, so that there is a
risk of not fully ablating all transcripts of the gene of interest.
In the case of the keratins, these genes and their transcripts
have been well studied and no alternate splicing has been
reported. Furthermore, the human genome project has made
available many expressed sequence tags that align to the K6a
and K6b genes and none of these show alternate splicing
(http://genome.ucsc.edu). Thus, with keratin genes at least,
the 30-UTR sequences represent a good target for siRNA. In
fact, the potency of our K6a 30-UTR inhibitors was so great
that even Coomassie blue staining readily showed their
powerful inhibitory effects (Figure 2a). When one considers
how abundant keratin mRNAs and proteins are within the
cytoplasm of keratinocytes and keratinocyte cell lines (Lane,
1993), it is remarkable to see near-ablation at the protein
level with picomolar amounts of siRNA.
The coding sequences of keratins show a high degree of
sequence conservation and therefore exploiting the K6a 30-
UTR sequence, which is similar to intronic or intergenic
sequences in terms of its poor intergene and interspecies
conservation, has the further advantage of avoiding potential
off-target effects against any of the other 52 functional keratin
genes in the human genome in addition to its closest relative,
K6b. Only one of the four siRNAs identified here, K6a-S3,
showed any off-target effects against the more distantly
related lamin A/C, which may be due to the presence of
repeat sequences within this particular target. This leaves
three lead inhibitors for further development and of these,
one has already been shown to be effective in an in vivo
mouse footpad model (Figure 4).
From studies of animal models of keratin disorders, it is
predicted that perhaps even partial reduction of a mutant
keratin allele might lead to significant improvement in the
clinical phenotype. Specifically, studies of mice with
inducible dominant-negative mutations in K14 (an inducible
mouse model of epidermolysis bullosa simplex), have
demonstrated in mice that even 50% knockdown of the
mutant allele would prevent the development of epidermal
blistering (Cao et al., 2001). There remains the issue of the
structural and physiological differences between mouse and
human epidermis, particularly in terms of the levels of
mechanical stress experienced in everyday life; however,
these data strongly emphasize the potential of even partial
gene inhibition as a route to therapy for many human keratin
disorders, including PC.
As we have demonstrated here, siRNA technology has
great potential as a therapeutic approach for treatment of
dominant-negative skin diseases. The reagents themselves fall
somewhere between small molecules and gene therapy in
terms of their size and chemical characteristics and so the
major hurdle now faced in the development of siRNA for
therapeutic use is the problem of delivery through the stratum
corneum into the living epidermis. Despite the advantage of
skin as one of the most accessible organs in the body, one of
its primary functions is to provide a physical barrier to
prevent the entry of foreign pathogens, allergens, and
irritants. As highlighted in a recent conference/workshop to
discuss obstacles to research translation with particular
emphasis on dermatology (Epstein et al., 2006), delivery into
skin is an area that requires further work if siRNA therapy for
PC or other skin diseases is to become a reality. A further
problem with keratinizing disorders such as PC is that the
very thick keratoderma would potentially act as a further
barrier to impede the entry of the inhibitor into the living cells
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experiments (for example, the positive control footpad in mouse 4 did not express the reporter gene at all), several replicates were carried out and the
bioluminescence signals captured with the Xenogen IVIS system were averaged and plotted. Five mice from the day 2 time point are shown. (b) Quantitation of K6a-
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the inherent variability of these experiments; however, the normalized siRNA data show consistent and highly potent knockdown of the K6a reporter gene.
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of the epidermis where the gene-silencing effect is required,
at least in the early stages of treatment.
In conclusion, we show that targeting the 30-UTR of the
K6a gene allows both potent and specific inhibition of K6a
expression both in cultured cells and early in vivo studies.
Coupled with a suitable epidermal delivery system, these
reagents could provide a potential route to therapy for PC, an
incurable and highly debilitating genetic skin disorder.
MATERIALS AND METHODS
siRNA design
Four siRNAs (designated K6a-S1, -S2, -S3, and -S4) were designed
(19þ 2 format) against the unique 30-UTR region of K6a (Table 1)
and synthesized by Dharmacon Inc., (Layfayette, CO). Lamin A/C
and EGFP-specific siRNAs were used as controls (Dharmacon).
Expression constructs
A wild-type K6a fusion protein tagged with EYFP was generated as
described previously (Hickerson et al., 2006). To make a dual
expression plasmid for expression of epitope-tagged versions of K6a
and K6b, a full-length human K6a IMAGE clone 3639270 was
subjected to site-directed mutagenesis using the Stratgene Quik-
Change system. Specifically, the termination codon was ablated and
replaced by a unique RsrII restriction site, allowing in-frame
insertion of an oligo cassette, with RsrII cohesive ends, encoding
the FLAG epitope DYKDDDDK, followed by an in-frame stop. By
the same strategy, the termination codon of a full-length K6b IMAGE
clone 4754558 was replaced by an RsrII site allowing insertion of an
oligo cassette encoding the myc epitope EQKLISEEDL. The FLAG-
tagged K6a construct was blunt-cloned into the XhoI site of the
pBudCE4.1dual expression plasmid (Invitrogen, Paisley, UK) for
expression under the EF-1a promoter; the myc-tagged K6b construct
was blunt-cloned into the XbaI site of pBudCE4.1 for expression
under the cytomegalovirus promoter. A bicistronic construct
expressing both firefly luciferase (fLUC) and wild-type K6a was
prepared as described previously (Hickerson et al., 2006).
Transient transfections
Human 293FT embryonic kidney cells (Invitrogen) were maintained
in DMEM (Sigma Chemicals, Poole, UK) supplemented with 10%
fetal bovine serum (Invitrogen). Cells were seeded onto 48-well
plates at 8 104 cells/well on the day before transfection. At
approximately 80% confluence, they were transfected using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. Cells were co-transfected with K6a-EYFP (150 ng) and
the specific K6a 30-UTR siRNAs (K6a-S1, -S2, -S3, or -S4) or a non-
specific control (NSC4) siRNA (final concentration of 0.016–4 nM)
supplemented with pUC19 plasmid DNA to give a final nucleic acid
concentration of 800 ng per transfection. Cells were visualized by
fluorescence microscopy (Olympus CK40) 48 hours following
transfection using an EGFP filter set. To quantitate siRNA inhibition,
cells were trypsinized 48 hours after transfection and analyzed by
FACS (Becton Dickinson FACScan) using channel FL1 (530 nm
emission filter). Ten thousand cells per transfection were analyzed.
The data were generated by gating the cells and determining the
percentage of cells that decreased below the gate with and without
siRNA treatment. The data were normalized to 100 and then
corrected against data from cells treated with NSC4 siRNA.
HaCaT (Boukamp et al., 1988) and NEB-1 cells (Morley et al.,
2003) were routinely grown in DMEM plus 10% fetal bovine serum.
NEB-1 cells were grown in RMþ medium, which consisted of
DMEM containing 25% Ham’s F12 medium (Sigma), 10% fetal
bovine serum, plus additional growth factors (hydrocortisone (0.4mg/
ml), cholera toxin (1010 M), transferrin (5 mg/ml), lyothyronine
(2 1011 M), adenine (1.9 104 M), and insulin (5 mg/ml)). All cell
lines were fibroblast feeder cell-independent and were cultured at
371C in 5% CO2.
HaCaT and NEB-1 cells were transfected using Lipofectamine
RNAiMax (Invitrogen) according to the manufacturer’s protocol for
‘‘reverse transfection.’’ Each K6a siRNA or lamin A/C control siRNA,
was diluted in 500ml Opti-MEM medium (Invitrogen). Lipofectamine
RNAiMax (7 ml) was added, mixed, and incubated at room
temperature for 20 minutes. Trypsinized HaCaT or NEB-1 cells
(2.5 105 cells in 2.5 ml growth medium) were added to each 3 cm2
plate. The final siRNA concentration was 5 nM. Cells were incubated
at 371C for 24, 48, 72, 96, and 120 hours.
Human AD293 embryonic kidney cells (Graham et al., 1977)
were maintained in DMEM plus 10% fetal bovine serum. Cells were
seeded onto 3 cm2 plates and transfected at 80–90% confluence
using Lipofectamine 2000 according to manufacturer’s instructions.
Briefly 500 ng plasmid pBudCE4.1 vector (Invitrogen), co-expressing
K6a-FLAG and K6b-c-Myc were diluted in 250 ml Opti-MEM
medium and K6a 30-UTR siRNAs or lamin A/C siRNA added.
Lipofectamine 2000 (3ml) was diluted in 250 ml Opti-MEM medium.
Diluted Lipofectamine 2000 and diluted DNA/siRNA were mixed
together, incubated at room temperature for 20 minutes and added to
the cells. The final siRNA concentration was 0.25 nM. Cells were
incubated at 371C for 48 hours.
Protein biochemistry
Cultured cells were washed twice with phosphate-buffered saline
and scraped from wells. For total protein extracts, cells were pelleted
at 1,000 r.p.m. for 5 minutes, and resuspended in 400 ml NuPAGE
lithium dodecyl sulfate sample buffer (Invitrogen).
For cytoskeletal extracts, cultured cells were washed twice with
phosphate-buffered saline, followed by incubation on ice in low salt
buffer (10 mM Tris–HCl, 150 mM NaCl, 3 mM EDTA, 0.1% NP-40 (pH
7.4) with HCl) for 20 minutes. The buffer was replaced with high salt
buffer (10 mM Tris–HCl, 150 mM NaCl, 1.5 M KCl, 3 mM EDTA, 0.1%
NP-40, pH 7.4) and incubated for a further 20 minutes on ice. Cells
were scraped off and pelleted at 3,500 r.p.m. for 15 minutes. Pellets
were washed three times in wash buffer (10 mM Tris–HCl, 150 mM
NaCl, 3 mM EDTA, pH 7.4) and centrifuged for 15 minutes at
3,500 r.p.m. between washes. Final pellets were resuspended in
200ml NuPAGE lithium dodecyl sulfate sample buffer (Invitrogen).
All extraction and washing buffers contained protease inhibitor
cocktail (0.1%, Sigma).
Cytoskeletal/total protein samples were heated to 701C for
10 minutes in the presence of reducing agent (final concentration
of 50 mM dithiothreitol; Invitrogen), and resolved on 4–12% NuPAGE
Bis/Tris gels (Invitrogen) with SDS-MOPS running buffer. SeeBlue
Prestained Standards (5 ml; Invitrogen) were run alongside as protein
size markers. Gels were either stained with SimplyBlue SafeStain
(Invitrogen) or transferred to nitrocellulose membrane for immuno-
staining. Efficiency of transfer and equal loading of samples was
confirmed by staining with Ponceau S solution (Sigma). Membranes
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were blocked in TBS (10 mM Tris–HCl (pH 8.0), 0.15 M NaCl)
containing 5% marvel and/or 0.05% Tween-20 (Sigma) for between
1–4 hours.
Immunoblotting
Keratin expression was detected by immunoblotting using 1 hour
incubations of the following primary antibodies: 1:200 dilution anti
K6 (Ks6.KA12; Progen Biotechnik, GmbH, Heidelberg, Germany);
1:500 dilution anti K17 (CK-E3, Sigma); anti K16 (LL025); anti K5
and K8 (RCK102); 1:1,000 anti K14 (LL001); 1:10 anti K19 (LP2K);
1:2 dilution anti K18 (LDK18); 1:10,000 dilution anti K5 (BL18)(all
kindly donated by E.B. Lane, College of Life Sciences, University of
Dundee, Dundee, UK); 1:200 dilution lamin A/C (Santa Cruz
Biotechnology, Santa Cruz, CA); 1:1,000 dilution anti-FLAG tag
rabbit polyclonal (anti-DDDDK tag.ab1162; Abcam Ltd, Cambridge,
UK); and 1:800 dilution 9E10 anti c-Myc (BD Biosciences
Pharmigen, Cowley, UK). After primary antibody incubation, blots
were washed three times for 5 minutes in 0.05% Tween-20/TBS and
incubated in secondary antibodies (1:1,000 dilution of either
alkaline phosphatase-conjugated rabbit anti-mouse immunoglobu-
lins (D314, DakoCytomation, Ely, UK) or goat anti-rabbit immuno-
globulins (D487) for 1 hour. Blots were washed as above and
developed using nitro blue tetrazolium and 5-bromo-4-chloro-3-
indolyl-phosphate color substrate (Promega, Southampton, UK).
Mouse footpad injections and in vivo imaging
Footpad injections into 6–8-week female FVB mice were performed
as described previously (Wang et al., 2007). Phosphate-buffered
saline (50 ml) containing 10mg of expression plasmid and 15mg
siRNA inhibitor (or pUC18 plasmid DNA) was intradermally injected
(28G needle). At the indicated time points, the mice were imaged
(10 minutes after intraperitoneal injection of 100 ml of 30 mg/ml
(150 mg/kg body weight) luciferin (Xenogen Biosciences, Cranbury,
NJ)). Mice were anesthesized using isoflurane and imaged using the
IVIS200 system (Xenogen Biosciences). Emitted light was quantitated
with LivingImage software (Xenogen). The raw data (photons/
second/cm2/srad) from footpads treated with K6a-S1 or EGFP siRNAs
were corrected by dividing by the amount of light emitted from
control footpads receiving pUCC18 in place of siRNAs.
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